^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    2d
    TD-NEOE3V3: Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=390, Not yet recruiting, Tang-Du Hospital | Initiation date: May 2025 --> Feb 2026
    Trial initiation date
    |
    cisplatin • docetaxel • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    2d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    2d
    Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=69, Recruiting, Oncomatryx Biopharma S.L.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • OMTX705
    2d
    SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC (clinicaltrials.gov)
    P3, N=318, Recruiting, West China Hospital | Not yet recruiting --> Recruiting | N=120 --> 318
    Enrollment open • Enrollment change • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    2d
    STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1021, Active, not recruiting, Gilead Sciences | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK mutation • RET mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    3d
    A Phase II Clinical Study of Sequential Iparomlimab and Tuvonralimab Combined with Chemotherapy Following Local Radiotherapy in Breast Cancer Patients with Poor Response to Neoadjuvant Chemotherapy (ChiCTR2600117206)
    P=N/A, N=30, Not yet recruiting, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    carboplatin • albumin-bound paclitaxel • epirubicin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    A Single-Arm Prospective Clinical Study on the Efficacy of Neoadjuvant Therapy with Toripalimab Combined with TP Regimen for Locally Advanced Head and Neck Tumors (ChiCTR2600117056)
    P=N/A, N=30, Not yet recruiting, The First People's Hospital of Yunnan Province; The First People's Hospital of Yunnan Province
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel
    3d
    Safety and efficacy of albumin-bound paclitaxel in combination with immunotherapy as second-line treatment for malignant biliary tract tumors (ChiCTR2600116737)
    P=N/A, N=40, Not yet recruiting, the Second Affiliated Hospital of Nanchang University; the Second Affiliated Hospital of Nanchang University
    New trial
    |
    albumin-bound paclitaxel
    3d
    A single-center, single-arm clinical study on the efficacy and safety of Iparomlimab and Tuvonralimab combined with chemotherapy as neoadjuvant therapy in patients with muscle-Invasive bladder cancer (MIBC) (ChiCTR2500115561)
    P=N/A, N=20, Not yet recruiting, Tianjin Cancer Hospital Airport Hospita; Tianjin Cancer Hospital Airport Hospita
    New trial
    |
    carboplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    Prospective, Open-Label, Single-Center Clinical Study of Iparomlimab and Tuvonralimab Combined with AG Regimen plus SBRT versus Epalolitovorimab Combined with AG Regimen as First-Line Treatment for Unresectable Locally Advanced or Metastatic Pancreatic Cancer (ChiCTR2500115120)
    P=N/A, N=40, Not yet recruiting, The First Affiliated Hospital of University of science and technology of China; The First Affiliated Hospital of University of science and technology
    New trial
    |
    gemcitabine • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study (ChiCTR2500114484)
    P=N/A, N=34, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    3d
    A study on the efficacy and safety of iparomlimab and tuvonralimab (QL1706) in combination with gemcitabine and albumin-bound paclitaxel (GA) as first-Line therapy for advanced cholangiocarcinoma (ChiCTR2500114460)
    P=N/A, N=25, Not yet recruiting, Yunnan Cancer Hospital; Yunnan Cancer Hospital
    New trial
    |
    gemcitabine • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)